Study S002289

Efficacy and Safety of First Line Use of Oral Semaglutide 25 mg or 50 mg Once Daily Versus Empagliflozin 25 mg or Versus Metformin 2000 mg in Newly Diagnosed Treatment naïve Patients With Type 2 Diabetes

ClinicalTrials.gov record

Registration

Registration: NCT06083675
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: WITHDRAWN
Enrollment: 0
Start: 2024-01-26
Primary completion: 2025-01-24
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:Semaglutide; DRUG:Empagliflozin; DRUG:Metformin
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1291-4976

Registered primary outcomes

Change in glycated haemoglobin (HbA1c) [From randomisation (week 0) to week 52]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.